Samjin Pharmaceutical Co.;Samjin Pharmaceutical Co., Ltd.; Ltd.;Incheon University Industry Academic Cooperation Foundation;Bamichem Co., Ltd.
发明人:
Lee, Jae Woong,Joo, Jeong Ho,Lee, Keun Kuk,Kim, Jong Min,Park, Yong Bin,Kang, Sung Hyun,Cho, Hyoung Min,Kim, Hyun Tae,Ahn, Soon Kil,Hong, Sung Pyo,Kim, Sung Hye,Cho, Eui Hwan,Shin, Hee Jong,Ki, Min Hy
申请号：
AU2017215928
公开号：
AU2017215928A1
申请日:
2017.01.11
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.
